Cara Therapeutics, Inc. (Nasdaq: CARA) today announced statistically significant topline results from its Phase 2 trial of its lead kappa ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Hot FDA News Management Comments

Cara Therapeutics (CARA) PT Raised to $34 at Piper JaffrayJuly 24, 2015 11:30 AM Cara Therapeutics (CARA) Fair Value Target Lifted to $27 at Janney CapitalJuly 23, 2015 10:45 AM Cara Therapeutics (CARA) PT Raised to $27 at Needham & CompanyJuly 23, 2015 9:50 AM Cara Therapeutics Announces Positive Results From Phase 2 Trial in Uremic PruritusJuly 23, 2015 7:01 AM